UBS Downgrades Sanofi to Neutral; Recent Downgrades Signal Cautious Outlook on SNY

UBS downgrades Sanofi (SNY) from Buy to Neutral, citing a cautious outlook. Recent downgrades from major financial institutions signal a shift in sentiment towards the company. Sanofi develops and markets drugs in immunology, vaccines, and rare diseases, with Dupixent generating approximately 30% of total sales. The average one-year target price for SNY is $59.51, implying an upside of 25.36% from the current price. The estimated GF Value for SNY in one year is $65.82, suggesting a 38.66% upside.